

Name	Program Description	Issuing Institute	Due Date	# of pages	Amount	Duration
<u>The Early Detection Research Network: Biomarker Developmental Laboratories (U01)</u>	Discovery, development, characterization, and testing of biomarkers of early cancer or risk; Development of relevant technologies for biomarker detection; development of analytical tools for the evaluation of biomarkers. <i>Collaborative interaction with NCI Alliance for Nanotechnology in Cancer</i>	NCI	Oct 29th; LOI due Sept 29th	40	600K/yr direct costs	5 yrs
<u>Partnerships for Development of Therapeutics and Diagnostics for Drug-Resistant Bacteria and Eukaryotic Parasite (R01)</u>	translational research leading to development of therapeutic and diagnostic technologies for drug-resistant bacteria and eukaryotic parasites; <i>Use of nanotechnology, microfluidic-based systems or any other novel or innovative system to process large numbers of patient samples</i>	NIAID	Nov 9th; LOI due on Oct 9th;	25	750k annual direct costs	5 yrs
<u>Partnerships for Development of Therapeutics and Diagnostics for Drug-Resistant Bacteria and Eukaryotic Parasites (SBIR [R43/R44])</u>	Small Business Innovation Research application for translational research leading to development of therapeutic and diagnostic technologies for drug-resistant bacteria and eukaryotic parasites; <i>Use of nanotechnology, microfluidic-based systems or any other novel or innovative system to process large numbers of patient samples</i>	NIAID	Nov 9th; LOI due on Oct 9th;	Phase I : 15 Phase II: 25 Fast-track: 25	Phase I: 500K/yr Phase II : 1M/yr	Phase I: 2 yrs Phase II: 3 yrs
<u>Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21)</u>	Support research by underrepresented groups to improve diversity in research in cancer cell biology, cancer etiology, cancer immunology, and hematology, DNA, and chromosome aberrations, structural biology, and the tumor microenvironment. <i>Includes investigations of cancer-related nanotechnology.</i>	NCI	Nov 23, June 23; LOI due on Oct 23, May 23	15	275K in total	2 yrs
<u>Cutting-Edge Basic Research Awards (CEBRA) (R21)</u>	Test a highly novel and significant hypothesis for which there is scant precedent or preliminary data and which, if confirmed, would have a substantial impact on current thinking; and/or develop or adapt innovative techniques or methods for addiction research, or that have promising applicability to drug abuse research. <i>Includes application of novel or emerging technologies (such as nanotechnology)</i>	NIDA	Dec 21st, Aug 20th	6	125K/yr direct costs	2 yrs
<u>Image-guided Drug Delivery in Cancer (R01)</u>	Development of integrated imaging-based platforms for multifunctional and multiplexed drug delivery systems in cancer. <i>Includes applications of nanotechnologies to cancer, nanocarriers, imaging contrast agents, therapeutics, nanovectors.</i>	NCI	Feb 5; June 5; Oct 5	25	500k/ yr direct costs	5 yrs